

## SpectraCure presentations at investor meetings this fall

<u>SpectraCure</u> will be presented at Småbolagsjakten Live, September 25th and at at Stora Aktiedagen, November 4th.

## SpectraCure will be presented at Småbolagsjakten Live, September 25th

Welcome to come and listen when the CEO of <u>SpectraCure</u>, Masoud Khayyami, holds a company presentation at the investor meeting Småbolagsjakten Live.

The event has attracted great interest and is already sold out. Do not despair if you haven't got a seat – the event will be broadcast live in the Facebook group

Aktier – Småbolagsjakten on investerarbrevet.se.

When? September 25th, at 7.50 pm.

Where? GT30, Bond, Grev Turegatan 30, Stockholm

## SpectraCure at Stora Aktiedagen, November 4th

A second chance to listen to Masoud Khayyami, CEO of SpectraCure, is given at <u>Stora Aktiedagen</u> in Gothenburg. The event will be streamed at <u>aktiespararna.se</u>.

Further details regarding Stora Aktiedagen will be shared as soon as the programme is fixed.



For further information, contact: SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46-(8)-503 000 50.

## SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region